Boehringer Ingelheim Launches Phase III COPD Drug Trial
The international study evaluates the efficacy of verducatib for adults with neutrophil-driven COPD.
Updated on Oct. 30, 2026 in Asthma
Live Poll
Should pharmaceutical companies prioritize new research for chronic conditions like COPD?
Boehringer Ingelheim has registered the AIRWARD Phase III clinical trial to test the efficacy and safety of the investigational drug verducatib. The global study targets adults suffering from COPD who have blood eosinophil counts below 300 cells/µL.
Why it matters
The trial aims to address the significant unmet medical need for treatments that target the underlying drivers of COPD exacerbations. Because most COPD cases involve neutrophil-driven inflammation, this drug could offer a new therapeutic pathway for patients.
The global trial includes 1,800 participants across 450 sites in over 25 countries. Researchers will monitor the annualized rate of moderate or severe exacerbations over an observation period of 52 to 76 weeks.
The players
Boehringer Ingelheim
This is a global research-driven pharmaceutical company headquartered in Ingelheim, Germany, and Ridgefield, Connecticut.
The details
Verducatib is a dipeptidyl peptidase 1 inhibitor designed to manage conditions where neutrophil-driven inflammation is prevalent. The study utilizes a randomized, double-blind, placebo-controlled design to assess outcomes in a population where 60 to 90 percent of individuals exhibit this inflammatory profile.
Timeline
Boehringer Ingelheim registered the AIRWARD Phase III trial on October 30, 2026.
The Big Picture
This research follows the parameters set by the AIRWARD clinical trial study details, which serves as a global benchmark for measuring COPD exacerbations. It represents a systematic effort to move beyond symptom management toward targeting specific inflammatory drivers of chronic respiratory illness.
While the drug is not yet available, this trial establishes a potential new treatment pathway for adults with specific inflammatory profiles. Patients should consult their doctors regarding clinical trial eligibility if they suffer from COPD and meet the study criteria.
The takeaway
This trial represents a shift in focus toward managing the specific biological triggers of COPD rather than just generalized airway obstruction. Participants in similar research often provide data that informs the future standard of care for millions globally.
Further reading
For more information on respiratory health, visit the Asthma research section.
More information
Review the full AIRWARD clinical trial study details via the government registry.
Live Poll
Should pharmaceutical companies prioritize new research for chronic conditions like COPD?
